Novel thienopyrrole glycogen phosphorylase inhibitors: synthesis, in vitro SAR and crystallographic studies.
Whittamore, P.R., Addie, M.S., Bennett, S.N., Birch, A.M., Butters, M., Godfrey, L., Kenny, P.W., Morley, A.D., Murray, P.M., Oikonomakos, N.G., Otterbein, L.R., Pannifer, A.D., Parker, J.S., Readman, K., Siedlecki, P.S., Schofield, P., Stocker, A., Taylor, M.J., Townsend, L.A., Whalley, D.P., Whitehouse, J.(2006) Bioorg Med Chem Lett 16: 5567-5571
- PubMed: 16945526 
- DOI: https://doi.org/10.1016/j.bmcl.2006.08.047
- Primary Citation of Related Structures:  
2GJ4, 2GM9 - PubMed Abstract: 
Two series of novel thienopyrrole inhibitors of recombinant human liver glycogen phosphorylase a (GPa) which are effective in reducing glucose output from rat hepatocytes are described. Representative compounds have been shown to bind at the dimer interface site of the rabbit muscle enzyme by X-ray crystallography.
Organizational Affiliation: 
AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. paul.whittamore@astrazeneca.com